0
+
0
+
Expert Speakers
0
+
Companies Represented
0
+
Senior Attendees
0
+
Expert Speakers
0
+
Companies Represented
Attendance from
Biopharma & Big Pharma
100%
Decision Makers
Decision Makers
By Geography
Day 1 | 24 February 2027 |
Day 2 | 25 February 2027 |
|
|
|
Ireland’s Peptides & Oligonucleotides Industry
|
CMC, Regulatory & Quality-by-Design Strategy
|
| Networking Break | |
|
Analytical Characterisation & Quality Control
|
Supply Chain Resilience & Capacity Strategy
|
| Lunch | |
|
Manufacturing & Process Development
|
Smart Aseptic Fill-Finish
|
| Networking Break | |
|
Roundtable Session: Advancing Peptide & Oligonucleotide Development
|
Shaping the Future of Peptide & Oligonucleotide Manufacturing
|
| End of Conference Day 1 | End of Conference |
Day 1 | 24 February 2027 |
|
|
|
Ireland’s Peptides & Oligonucleotides Industry
|
| Networking Break |
|
Analytical Characterisation & Quality Control
|
| Lunch |
|
Manufacturing & Process Development
|
| Networking Break |
|
Roundtable Session: Advancing Peptide & Oligonucleotide Development
|
| End of Conference Day 1 |
Day 2 | 25 February 2027 |
|
|
|
CMC, Regulatory & Quality-by-Design Strategy
|
| Networking Break |
|
Supply Chain Resilience & Capacity Strategy
|
| Lunch |
|
Smart Aseptic Fill-Finish
|
| Networking Break |
|
Shaping the Future of Peptide & Oligonucleotide Manufacturing
|
| End of Conference |
DAY 1
24 February 2027
08:55
Chairman’s Welcome Address
09:00
Driving Innovation in Peptide & Oligonucleotide Manufacturing in Ireland
- Emerging technologies in synthesis, purification, and analytics
- Process intensification strategies for higher yield and efficiency
- Leveraging Ireland’s manufacturing ecosystem for collaborative R&D
- Case studies of recent innovations in oligo and peptide production
09:25
Solution Provider
Reserved for Solution Provider
09:50
Panel Discussion
Leading the Future of Peptide and Oligonucleotide Manufacturing: Strategies for Resilience, Digital Transformation, and Innovation in Ireland
- Leadership perspectives on driving digital adoption across manufacturing and supply chains
- Strategic approaches to enhance operational resilience and risk mitigation
- Collaborations between industry, academia, and CDMOs to accelerate innovation
- Balancing regulatory compliance, process efficiency, and scalable manufacturing
11:00
Advanced Analytical Techniques for Peptide & Oligonucleotide Therapeutics
- Implementation of high-resolution methods such as LC-MS and HPLC for complex molecules
- Detecting and controlling impurities, modifications, and degradation products
- Optimising sample preparation and method sensitivity for challenging therapeutics
- Ensuring analytical comparability across clinical and commercial batches
11:25
Solution Provider
Reserved for Solution Provider
11:50
Integrating Real-Time Monitoring and Process Analytical Technology (PAT)
- Leveraging real-time monitoring for upstream and downstream processes
- Early detection of deviations to maintain consistent product quality
- Supporting automation and predictive analytics to optimise manufacturing performance
- Enabling real-time release testing to accelerate product availability
13:15
Building the ADAR Chemistry Toolbox: Engineering the Phosphorus Backbone with Safer Chemistries for Next-Generation ASOs
Juergen Mueller
Head of Chemistry & Managing Director, AIRNA, Switzerland
14:00
Solution Provider
Reserved for Solution Provider
14:25
Optimising Downstream Process Development for Scalable and Robust ASO Manufacturing
Armin Delavari
Senior Scientist, Technical Development, Biogen, US
15:30
Roundtable Discussion
How Cross-Industry Collaboration is Accelerating Innovation and Driving Growth in Peptide and Oligonucleotide Manufacturing
Identifying Emerging Trends and Opportunities to Shape the Future of Oligos & Peptides
Enhancing Cross-Functional Collaboration Across Manufacturing Teams
Driving Operational Excellence and Innovation Through Industry Collaboration
Topic: TBC
Sunay Chankeshwara
Associate Principal Scientist, AstraZeneca, Sweden
DAY 2
25 February 2027
08:55
Chairman’s Welcome Address
09:00
Applying MSAT Principles to Accelerate CMC Readiness and Commercial Manufacturing of Complex Injectable Therapies
Dr Dikshitkumar Khamar
Senior Director, Head of Scientific Excellence, MSAT Injectables, Sanofi, Ireland
09:25
Solution Provider
Reserved for Solution Provider
09:50
Applying Quality-by-Design Principles to Optimise Manufacturing and Product Consistency
- Embedding QbD from early development to commercial scale
- Ensuring reproducibility and comparability across sites
- Preparing for regulatory inspections and approvals
- Cross-functional collaboration for continuous improvement
10:45
From Risk Management to Operational Resilience: Designing Successful Commercial Launches
- Designing resilient operating models, not just compliant processes
- Identifying risks before they become operational disruptions
- Eliminating critical dependencies and single points of failure across the value chain
- Balancing resilience, agility and commercial readiness to ensure successful product launches
Peter Coughlan
Associate Director - Supply Chain Risk Management, Alkermes, Ireland
11:10
Solution Provider
Reserved for Solution Provider
11:25
Panel Discussion
Capacity Planning and Operational Excellence to Maximise Throughput and Reliability
- Aligning production planning with pipeline growth
- Resource and workforce allocation strategies
- Ensuring consistent quality across multiple sites
- Lessons from real-world capacity challenges and solutions
13:00
Implementing Automation and Advanced Technologies to Achieve Efficient and Reliable Aseptic Fill-Finish Operations
- Integration of robotics and automated systems for consistent production
- Reducing contamination risk and human error in sterile processes
- Streamlining workflows to maximise throughput and flexibility
- Case studies demonstrating successful automation adoption
13:25
Solution Provider
Reserved for Solution Provider
13:50
Enhancing Quality, Reliability, and Operational Performance Through Data-Driven Fill-Finish Strategies
- Real-time monitoring and predictive maintenance using PAT
- Integrating upstream and downstream processes for operational efficiency
- Maintaining sterility and regulatory compliance
- Operational lessons from commercial-scale implementation
14:45
Advancing Oligonucleotide Chemistry from Development to Scalable Drug Substance Manufacturing
Peter D Smith
Director, New Modalities Chemistry, AstraZeneca, UK
15:10
Strategic Innovations Driving Peptide & Oligonucleotide Manufacturing in Ireland
- Emerging technologies shaping manufacturing workflows and process efficiencies
- Leveraging Ireland’s biopharma ecosystem for collaboration and innovation
- Optimising scale-up strategies from clinical to commercial production
- Integrating digitalisation and process analytics to improve throughput and quality
15:40
Emerging Opportunities and Future Trends in Biopharmaceutical Manufacturing
- Identifying growth areas in oligonucleotide and peptide therapeutics
- Opportunities for cross-functional collaboration and partnerships
- Implementing resilience strategies for supply chain, regulatory, and operational challenges
- Lessons learned from current manufacturing practices to inform future innovation
Attendance from
Biopharma & Big Pharma
100%
Decision Makers
Decision Makers
By Geography
Day 1 | 17 February 2027 |
Day 2 | 18 February 2027 |
|
|
|
Current State of Oligo & Peptides Manufacturing in DACH Region
|
Process Development & Scale-Up
|
| Networking Break | |
|
Analytical Characterization & Quality Control
|
Supply Chain and Outsourcing Strategies
|
| Lunch | |
|
Formulation and Delivery Strategies
|
Scaling Oligo & Peptide Manufacturing
|
| Networking Break | |
|
Industry Roundtables: The Future of Oligos & Peptides
|
CMC Strategy and Fill-Finish for Oligos & Peptides
|
| End of Conference Day 1 | End of Conference |
Day 1 | 17 February 2027 |
|
|
|
Current State of Oligo & Peptides Manufacturing in DACH Region
|
| Networking Break |
|
Analytical Characterization & Quality Control
|
| Lunch |
|
Formulation and Delivery Strategies
|
| Networking Break |
|
Industry Roundtables: The Future of Oligos & Peptides
|
| End of Conference Day 1 |
Day 2 | 18 February 2027 |
|
|
|
Process Development & Scale-Up
|
| Networking Break |
|
Supply Chain and Outsourcing Strategies
|
| Lunch |
|
Scaling Oligo & Peptide Manufacturing
|
| Networking Break |
|
CMC Strategy and Fill-Finish for Oligos & Peptides
|
| End of Conference |
DAY 1
17 February 2027
08:50
Chairman’s Welcome Address
Nicoletta Loggia
Chief Technology Officer, Orchard Therapeutics, Switzerland
09:00
Challenges in the Synthesis of Isotopically Labelled Peptides
Volker Derdau
Head Center of Excellence Isotope Chemistry, Senior Distinguished Scientist, Sanofi, Germany
09:30
Solution Provider
Reserved for Solution Provider
10:00
Panel Discussion
Overcoming Operational and Regulatory Challenges in the DACH Region
- Navigating regional regulatory expectations for complex oligos and peptides
- Strategies to address supply chain risks and raw material availability
- Integration of digital tools and analytics for process control and quality assurance
- Best practices for cross-site technology transfer and operational excellence
Panelists
Karoline Bechtold-Peters
Director Science & Technology - Scientific Office/Drug Product Development/Global Biologics & CGT, Novartis, Switzerland
11:10
Advanced Analytics for Oligos & Peptides
- LC-MS methods for complex peptides and oligonucleotides
- Impurity profiling and identification of critical quality attributes
- Stability-indicating methods to monitor degradation pathways
- Reference standards & method validation
11:40
Solution Provider
Reserved for Solution Provider
12:10
Digitalisation and Automation in QC Labs
- Integrating automated platforms for high-throughput analysis
- Real-time release testing: opportunities and limitations
- Predictive analytics and AI for process and product quality monitoring
- Data integrity, regulatory compliance, and digital record-keeping
14:00
Advanced Formulation Strategies for Stability, Efficacy and Developability of Biologics and Complex Modalities
- Designing robust formulations to improve stability and shelf-life of biologics and advanced therapies
- Managing aggregation, viscosity, and degradation challenges in high-concentration formulations
- Selecting optimal excipients and buffer systems for antibodies, ADCs, and novel modalities
- Integrating developability assessments early to reduce downstream formulation risks
14:30
Solution Provider
Reserved for Solution Provider
15:00
Innovative Drug Delivery Approaches for Next-Generation Biologics and Targeted Therapies
- Advancing delivery technologies for improved tissue targeting and therapeutic efficiency
- Overcoming biological barriers to enhance bioavailability and intracellular delivery
- Evaluating delivery systems such as nanoparticles, LNPs, and sustained-release platforms
- Aligning formulation design with clinical performance and patient-centric delivery requirements
16:00
Roundtable Discussion
AI-Powered Drug Discovery & Digital Innovation
Next-Generation Oligos & Peptides Modalities & Therapeutic Innovation
Advanced Delivery Technologies & Targeted Therapeutic Systems
Partnering for Success: The Future of Pharma-Biotech Collaboration in Oligos & Peptides
DAY 2
18 February 2027
08:50
Chairman’s Welcome Address
09:00
New Approach to Recombinant Peptides
- Next-generation recombinant peptide manufacturing
- Scaling peptide production efficiently
- Advances in purification & analytics
- Integrated CMC for recombinant peptides
Dr. Cecile Brocard
Head of Downstream Development, Boehringer Ingelheim, Austria
09:30
Solution Provider
Reserved for Solution Provider
10:00
Process Optimisation and Continuous Improvement for Complex Peptides and Oligonucleotides
- Process intensification strategies for complex peptides and oligonucleotides
- Implementing digital tools and automation to enhance process control
- Reducing variability and improving reproducibility across batches
- Lessons learned from troubleshooting scale-up challenges
11:10
Panel Discussion
Building Resilient and Agile Supply Chains for Biologics, Oligos and Peptides
- Strengthening end-to-end supply chain resilience in a volatile global environment
- Managing cold chain, logistics and distribution risks for complex modalities
- Improving visibility and digitalisation across global supply networks
- Aligning supply chain strategy with clinical, scale-up and commercial demand
11:40
Solution Provider
Reserved for Solution Provider
12:10
Strategic Outsourcing Models and CDMO Partnerships for Efficient Manufacturing
- Selecting the right CDMO partners across development and commercial stages
- Balancing in-house capabilities vs outsourcing for cost, speed and flexibility
- Strengthening governance, quality oversight and performance management of CDMOs
- Optimising tech transfer and collaboration models for seamless external manufacturing
Dr. Ulrich Rümenapp
Senior Biotech Program Lead, Bayer, Germany
14:00
Process Scale-Up Strategies for Efficient and Reproducible Oligonucleotide and Peptide Manufacturing
- Transitioning from lab-scale synthesis to GMP and commercial-scale manufacturing
- Managing scale-dependent challenges in solid-phase synthesis and purification
- Ensuring process robustness, reproducibility and batch-to-batch consistency
- Establishing scalable manufacturing platforms for clinical and commercial supply
14:30
Solution Provider
Reserved for Solution Provider
15:00
Overcoming Manufacturing and Quality Challenges in Large-Scale Oligo and Peptide Production
- Addressing impurity control and purification challenges during scale-up
- Optimising yield, cycle time and cost of goods (COGS) in large-scale production
- Ensuring analytical consistency and quality control across manufacturing scales
- Strengthening tech transfer and CDMO collaboration for seamless industrialisation
16:00
Integrated CMC Strategies for Efficient Development of Oligonucleotide and Peptide Therapeutics
- Strategies from early development to commercial manufacturing
- Managing complexity in synthesis, purification and analytical control for oligos and peptides
- Aligning process development with regulatory expectations and quality requirements
- Enabling scalable and robust manufacturing platforms for clinical and commercial success
Hagen Cramer
Chief Technology Officer, QurAlis, USA
16:30
Advancing Fill-Finish Operations for Oligonucleotides and Peptides: Ensuring Quality and Scalability
- Overcoming fill-finish challenges for low-dose, high-potency oligonucleotide and peptide drugs
- Ensuring product stability and integrity during formulation, filling and packaging
- Selecting appropriate primary packaging systems for different delivery formats
- Scaling aseptic fill-finish processes from clinical to commercial production
Dr Dikshitkumar Khamar
Senior Director, Head of Scientific Excellence, MSAT Injectables, Sanofi, Ireland
BIG PHARMA
Sunay Chankeshwara
Senior Peptide Expert (Associate Principal Scientist)
AstraZeneca
Sweden
BIG PHARMA
Armin Delavari
Senior Scientist, Technical Development
Biogen
US
Peter Coughlan
Associate Director - Supply Chain Risk Management
Alkermes
Ireland
BIG PHARMA
Ann De Saeger
Principal Scientist II
J&J Innovative Medicine
Belgium
Juergen Mueller
Head of Chemistry & Managing Director
AIRNA
Switzerland
BIG PHARMA
Dr Dikshitkumar Khamar
Senior Director, Head of Scientific Excellence, MSAT Injectables
Sanofi
Ireland
BIG PHARMA
Peter D Smith
Director, New Modalities Chemistry
AstraZeneca
UK
Barbara Barbosa
Global Medical Director
Vicore Pharma AB
Switzerland
BIG PHARMA
Volker Derdau
Head Center of Excellence Isotope Chemistry, Senior Distinguished Scientist
Sanofi
Germany
BIG PHARMA
Dr. Ulrich Rümenapp
Senior Biotech Program Lead
Bayer
Germany
BIG PHARMA
Dr. Cecile Brocard
Head of Downstream Development
Boehringer Ingelheim
Austria
Hagen Cramer
Chief Technology Officer
QurAlis
USA
BIG PHARMA
Karoline Bechtold-Peters
Director Science & Technology - Scientific Office/Drug Product Development/Global Biologics & CGT
Novartis
Switzerland
BIG PHARMA
Carl Reens
Principal Scientist, Global Chemical Development
AstraZeneca
UK
Gnana Oli Rajaraman
Associate Director Bioanalytics
AiCuris
Germany
Thought Leadership Speaking
Panel Participation
Solution Showcases
Engagement and Visibility Opportunities
Branding and Digital Visibility
Exclusive Networking
Past Partners for the Biologics Manufacturing Ireland & Oligos & Peptides Europe Series
DACH Series Past Partners
Dr Heiner Apeler
VP Head of Biologics Development
Bayer
Germany
The Biologics and CGT Manufacturing DACH conference 2026 was very well planned and coordinated. It provided high-quality talks for staying up-to-date in our industry and I specifically enjoyed the time for networking.
John Bridgeman
CSO
Immunokey
UK
Thanks for the invite to speak at the event. It was a really enjoyable meeting and a great opportunity to present our work to the community. Identifying key partners for ImmunoKey’s development plan is a critical aspect of getting our therapies to patients; the CGT and Biologics Manufacturing DACH meeting offered us the opportunity to engage with key CDMOs who can help us achieve this goal.
Dennis Stelljes
Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing
BMS
Switzerland
Just back from an incredible time at the Biologics Manufacturing DACH congress! I have to be honest - as someone in Procurement, some of the deep-dives into Cell & Gene and biologics development were definitely above my scientific capabilities! However, the exchange of knowledge was fantastic, and it was a privilege to learn from such brilliant minds. A true highlight was the fantastic collaboration with Christopher Pawlak (PhD) . I had the privilege of co-hosting a round table with him focused on the impact of tariffs in the biopharma world. Christoph, thank you for the partnership - it was a truly dynamic discussion! 🤝 One of my biggest takeaways is that we have officially entered the era of "The Great Reshoring". We are moving past the days when drug manufacturing decisions were purely scientific; they are now deeply geopolitical. As we discussed in our round table, we can no longer just react to change. We have to treat scenario planning like a muscle that we train constantly to design for volatility. The event really hit home how much our world is changing - from the incredible progress in biologics manufacturing to the AI evolution. I’m excited to see how we can implement these insights to build resilience and benefit BMS biologics manufacturing. Back to my desk, I will start with socializing the learnings with my colleagues. A huge thank you to Drishti G. for the flawless organization and to Noel Murphy for approving the trip and supporting this critical learning opportunity!
Dr Andrew Kelly
Director, Manufacturing Technology
BMS
Ireland
Really well organised conference with great attendees and high engagement - I was delighted to have taken the time to attend and really enjoyed sharing my thoughts on Accelerating Biologics Pipeline and ensuing discussion. Thank you to all organisers and facilitators
Dr Thomas Villiger
Professor of Bioprocess Technology
University of Applied Sciences and Arts Northwestern Switzerland FHNW
Switzerland
A fantastic deep dive into the DACH region’s CGT landscape. This conference made one thing clear: efficacy is proven, but industrialization is the new frontier. To truly move the needle, we must look beyond the lab and focus on scaling automation, streamlining supply chains, and tackling COGS. The diversity of voices - from large corporations, to tech suppliers and academic pioneers - provided a 360-degree view of the manufacturing challenges we must solve together.
Brian O'Connor
VP Global Quality
Orchard Therapeutics
UK
Thanks for the invite. The conference was really excellent, due to the caliber and engagement of the attendees.
Alvaro Avivar-Valderas
Associate Director - Cell Therapy Technology & Product Engine
Takeda
Spain
Thanks for putting this together! I enjoyed the discussions, atmosphere and engagement of participants. Great to be there!
Steffen Schulze
Strategic Analytics & Business Analytics Lead
Roche
Switzerland
I thoroughly enjoyed attending the CGT Manufacturing DACH 2026 by IMAPAC. The program featured exceptionally industry-relevant talks that provided deep insights into the current landscape. Beyond the sessions, the networking opportunities were top-tier, thanks to the high caliber of participants.
Terry Gray
Field Marketing Manager
Merck
I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team.
Warren Roche
Senior Statistical Expert
Sanofi
Ireland
Thank you for your email and organising this wonderful event. It was a pleasure to participate. Congratulations on organising this event. It was a wonderful opportunity to present our work and to collaborate with others in the area. Looking forward to your next event
Michael Inglis
Head of Manufacturing Sciences, Analytical Technologies
Chiesi Farmaceutici Global Rare Disease
Ireland
Thank you, it was a pleasure meeting you, and your enthusiasm made it an engaging and positive event.
I hope we have opportunity to connect again in the future.
Shada Warreth
Global Partnerships Implementation Senior Manager
NIBRT
Ireland
Well done on a very informative and successful event.
Radisson Blu Hotel, London Heathrow
140 Bath Road, Harlington, Hayes UB3 5AW, UK
Travel Options
By London Underground
From Heathrow Airport
Taxi or Ride-Hailing
By Car
From Other UK Cities
Accommodation Options
Explore recommended hotels near the venue.
Venue Hotel
Radisson Blu Hotel, London Heathrow
140 Bath Road, Hayes, Middlesex, UB3 5AW
venue for this event
To book a room at this hotel, please click the button below
London Heathrow Mariott Hotel
Bath Road Heathrow, Airport, Hayes UB3 5AN
4 minute walk from venue
To book a room at this hotel, please click the button below
Ibis Style London Heathrow Airport
272 Bath Rd, London UB3 5AY
8 minute walk from venue
To book a room at this hotel, please click the button below
Premier Inn London Heathrow
15 Bath Rd, London TW6 2AB
5 minute drive from venue
To book a room at this hotel, please click the button below
Please find the booth allocation in the table below.
4
Alfa Laval
11
QuickSTAT
12
BSP Pharmaceuticals
14
AsTec Chemicals
17
Unchained Labs
19
Inprocess LSP
18
Kemwell Biopharma
